Annexe 2

COMP Report to the European Commission in Relation to Article 10 of Regulation 141/2000 on Orphan Medicinal Products

ANNEX 2

Table 1: Centralised Marketing Authorisations for Orphan Medicinal Products – Status in May 2005

Medicinal Product	MAH/Sponsor	Designated Orphan Indication / Estimated Number of patients[1]	Grounds for designation	Date of Designation / Marketing Authorisation	Authorised Therapeutic Indication
Fabrazyme, recombinant human alfa galactosidase	Genzyme B.V.	Treatment of Fabry disease 1 200	No authorised treatments were available.	08.08.2000 03.08.2001	Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (a-galactosidase A deficiency)
Replagal, α-galactosidase A)	TKT Europe AS	Treatment of Fabry disease 1 200	No authorised treatments were available.	08.08.2000 03.08.2001	Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (a-galactosidase A deficiency)
Trisenox, Arsenic trioxide	Cell Therapeutics (UK) Ltd.	Treatment of acute promyelocytic leukaemia (APL) 91 900	Assumption of significant benefit.	18.10.2000 05.03.2002	TRISENOX is indicated for induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (APL), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. Previous treatment should have included a retinoid and chemotherapy. The response rate of other acute myelogenous leukaemia subtypes to TRISENOX has not been examined
Tracleer, Bosentan	Actelion Registration Limited	Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension 101 100	Assumption of significant benefit.	14.02.2001 15.05.2002	Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with grade III functional status. Efficacy has been shown in: Primary PAH PAH secondary to scleroderma without significant interstitial pulmonary disease

[1] Based on a population of 459,700,000 (Eurostat 2004)

Medicinal Product	MAH/Sponsor	Designated Orphan Indication / Estimated Number of patients	Grounds for designation	Date of Designation / Marketing Authorisation	Authorised Therapeutic Indication
Glivec, Imatinib mesylate	Novartis Europharm Limited	Treatment of chronic myeloid leukaemia 41 300	Assumption of significant benefit.	14.02.2001 07.11.2001	Glivec is indicated for the treatment of adult patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
				14.02.2001 19.12.2002 Variation	Glivec is indicated for the treatment of patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. Glivec is also indicated for the treatment of patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
		Treatment of malignant gastrointestinal stromal tumours 27 500	No authorised treatments were available.	20.11.2001 24.05.2002 Variation	Glivec is indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
Somavert, Pegvisomant	Pharmacia Enterprises S.A	Treatment of acromegaly 27 500	Assumption of significant benefit.	14.02.2001 13.11.2002	Treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated
Zavesca, Miglustat 1,5-(Butylimino)-1,5-dideoxy, D-glucitol	Oxford GlycoSciences (UK) Ltd.	Treatment of Gaucher disease 27 500	Assumption of significant benefit.	18.10.2000 20.11.2002	Zavesca is indicated for the oral treatment of mild to moderate type 1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable
Carbaglu, N-carbamyl-L-glutamic acid	Orphan Europe Sarl	Treatment of to N-acetylglutamate synthetase (NAGS) deficiency 46	No authorised treatments were available.	18.10.2000 24.01.2003	Treatment of hyperammonaemia due to N-acetylglutamate synthase deficiency

Medicinal Product	MAH/Sponsor	Designated Orphan Indication / Estimated Number of patients	Grounds for designation	Date of Designation / Marketing Authorisation	Authorised Therapeutic Indication
Aldurazyme, Laronidase	Genzyme Europe BV	Treatment of Mucopolysaccharidosis type I 1 100	No authorised treatments were available.	14.02.2001 10.06.2003	Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis I (MPS I; a [alpha]-L-iduronidase deficiency) to treat the non-neurological manifestations of the disease
Busilvex, Busulfan	Pierre Fabre Medicament	Conditioning treatment prior to haematopoietic progenitor cell transplantation 32 100	Assumption of significant benefit.	29.12.2000 09.07.2003	Conditioning treatment prior to haematopoietic progenitor cell transplantation in adult patients
Ventavis, Iloprost	Schering AG	Treatment of primary and of the following forms of secondary pulmonary hypertension: connective tissue disease pulmonary hypertension, drug-induced pulmonary hypertension, portopulmonary hypertension, pulmonary hypertension associated with congenital heart disease, chronic thromboembolic pulmonary hypertension 101 100	Assumption of significant benefit.	29.12.2000 16.09.2003	Treatment of patients with primary pulmonary hypertension, classified as NYHA functional class III, to improve exercise capacity and symptoms
Onsenal, Celecoxib	Pharmacia-Pfizer EEIG	Treatment of Familial Adenomatous Polyposis (FAP) 46 000	No authorised treatments were available.	20.11.2001 17.10.2003	Reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance
Photobarr, Porfimer sodium (for use with photodynamic therapy)	Axcan Pharma International BV	Treatment of high-grade dysplasia in Barrett's Esophagus 165 500	No authorised treatments were available.	06.03.2002 25.03.2004	Photodynamic therapy (PDT) with porfimer sodium is indicated for: - Ablation of high-grade dysplasia (HGD) in patients with Barrett's Esophagus (BE)
Litak, Cladribine	Lipomed GmbH	Treatment of indolent non-Hodgkin's lymphoma 167 800	Assumption of significant benefit.	18.09.2001 14.04.2004	Treatment of hairy cell leukaemia

Medicinal Product	MAH/Sponsor	Designated Orphan Indication / Estimated Number of patients	Grounds for designation	Date of Designation / Marketing Authorisation	Authorised Therapeutic Indication
Lysodren, Mitotane	Laboratoire HRA Pharma	Treatment of adrenal cortical carcinoma 4 600	Assumption of significant benefit.	12.06.2002 28.04.2004	Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established
Pedea, Ibuprofen	Orphan Europe SARL	Treatment of Patent Ductus Arteriosus 97 900	Assumption of significant benefit.	05.03.2001 29.07.2004	Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age
Wilzin, Zinc acetate dihydrate	Orphan Europe	Treatment of Wilson's disease 27 500	Assumption of significant benefit.	31.07.2001 13.10.2004	Treatment of Wilson's disease.
Xagrid Anagrelide Hydrochloride	Shire Pharmaceuticals Contracts Ltd	Treatment of essential thrombocythaemia 138 000	Assumption of significant benefit.	29.12.2000 16.11.2004	Xagrid is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: >60 years of age or A platelet count >1000 x 10E9/l or A history of thrombo-haemorrhagic events.
Orfadin, Nitisinone	Swedish Orphan International AB	Treatment of tyrosinaemia type 1 4 600	No authorised treatments were available.	29.12.2000 21.02.2005	Hereditary tyrosinemia type 1
Prialt, Ziconotide	Elan Pharma International Ltd.	Treatment of chronic pain requiring intraspinal analgesia 71 200	Assumption of significant benefit.	09.07.2003 21.02.2005	Ziconotide is indicated for the treatment of chronic pain requiring intrathecal (IT) analgesia in patients who fail to obtain adequate analgesia and/or suffer intolerable adverse events with systemic opioids

Table 2: National Marketing Authorisations for Orphan Medicinal Products – Status in May 2005

Medicinal Product	MAH/Sponsor	Designated Orphan Indication / Estimated Number of patients[2]	Grounds for designation	Date of Designation / Marketing Authorisation	Authorised Therapeutic Indication
Dudopa Levodopa/Carbidopa (Gastroenteral use)	NeoPharma	Treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations and not responding to oral treatment. 110 328	No authorised treatments were available.	10.05.2001 21.01.2004 in Sweden 08.06.2004 in Austria, Denmark, Finland, France, Germany, The Netherlands, Norway, Portugal, Spain	Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
Impavido, Miltefosine	Zentaris AG	Treatment of visceral leishmaniasis. 4 600	Assumption of significant benefit.	12.06.2002 19.11.2004 Germany	Treatment of visceral leishmaniasis caused by Leishmania donovani after failure of standard therapy.

[2] Based on a population of 459,700,000 (Eurostat 2004)